Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.05
- Piotroski Score 5.00
- Grade Market Perform
- Symbol (NLS)
- Company Nautilus, Inc.
- Price $0.82
- Changes Percentage (11.2%)
- Change $0.08
- Day Low $0.75
- Day High $0.86
- Year High $2.17
Nautilus, Inc., a fitness solutions company, designs, develops, sources, and markets cardio and strength fitness products, and related accessories for consumer and commercial use in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company operates in two segments, Direct and Retail. It offers specialized cardio products, treadmills, ellipticals, bike products, home gyms, dumbbells, barbells, and kettlebells primarily under the Nautilus, Bowflex, Octane Fitness, and Schwinn brands, as well as fitness digital platform under the JRNY brand. In addition, it engages in licensing its brands and intellectual properties. The company offers its products directly to consumers through television advertising, social media, websites, and catalogs; and through a network of retail companies consisting of sporting goods stores, online retailers, electronics stores, furniture stores, and large-format and warehouse stores, as well as specialty retailers and independent bike dealers. Nautilus, Inc. was founded in 1986 and is headquartered in Vancouver, Washington.
- Last Earnings 08/03/2007
- Ex-Dividend for 5/16 Dividend 08/16/2007
- Dividend Payable 09/10/2007
- Today N/A
- Next Earnings (Estimated) 11/06/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.63
- Trailing P/E Ratio -0.50331288343558
- Forward P/E Ratio -0.50331288343558
- P/E Growth -0.50331288343558
- Net Income $-107,488,000
Income Statement
Quarterly
Annual
Latest News of NLS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NLS and Kadimastem stocks soar following merger agreement
Switzerland's NLS Pharmaceutics and Israel's Kadimastem are merging to create a joint biopharmaceutical focusing on neurogenerative diseases and diabetes treatments. The merger deal includes stock iss...
By Yahoo! Finance | 2 weeks ago
